Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis最新文献_第7页

A single center study: the effect of in vitro lipemia on coagulation tests. 单中心研究：体外脂血症对凝血试验的影响。

IF 1.1

Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis Pub Date : 2026-04-01 Epub Date: 2026-02-11 DOI: 10.1097/MBC.0000000000001413

Melek Karasu, Aysegul Ozgenc, Dildar Konukoglu

{"title":"A single center study: the effect of in vitro lipemia on coagulation tests.","authors":"Melek Karasu, Aysegul Ozgenc, Dildar Konukoglu","doi":"10.1097/MBC.0000000000001413","DOIUrl":"10.1097/MBC.0000000000001413","url":null,"abstract":"Objective: Coagulation tests like prothrombin time (PT), activated partial thromboplastin time (aPTT), fibrinogen, international normalized ratio (INR), and D-dimer are vital for monitoring anticoagulant therapy and diagnosing blood disorders. Preanalytical factors such as lipemia, caused by high blood lipid levels after eating, lipid infusions, or metabolic diseases like diabetes, can affect test accuracy. In emergency departments, nonfasting samples increase lipemia risk. This study investigates how lipemia influences coagulation test results to improve diagnostic reliability in clinical settings.Material and method: Serial dilutions of 10% Oliclinomel parenteral lipid emulsion were prepared, and 1 ml of each dilution was mixed with plasma samples from 36 patients. The plasma pool was analyzed for PT, aPTT, fibrinogen, INR, and D-dimer using a Sysmex CS2500 analyzer, with triglyceride (TG) concentrations and lipemia index (LI) values measured by a Roche Cobas 6000 C501 analyzer. Bias (%) values were calculated and compared to target bias (%) values to determine cut-off LI values for each parameter.Results: Results showed that PT and fibrinogen were affected by higher TG concentrations, while aPTT was influenced by lower TG concentrations. The cut-off LI values for PT, aPTT, and fibrinogen were determined to be 300, 50, and 150, respectively. For D-dimer, the cut-off LI value was established at 1200.Conclusion: These findings highlight the importance of determining specific LI cut-off values for each laboratory and considering lipemia's effect on coagulation test results, particularly in emergency settings and in patients with dyslipidemia.","PeriodicalId":520571,"journal":{"name":"Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis","volume":" ","pages":"87-89"},"PeriodicalIF":1.1,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146159937","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Overcoming the PROSP pseudogene challenge: accurate diagnosis of a novel PROS1 variant in a patient with dural venous sinus thrombosis. 克服PROS1假基因的挑战：在硬脑膜静脉窦血栓患者中准确诊断新的PROS1变异。

IF 1.1

Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis Pub Date : 2026-03-17 DOI: 10.1097/MBC.0000000000001420

Vasant Kumar, Debadrita Ray, Manu Jamwal, Chander Hans, Arihant Jain, Jasmina Ahluwalia, Reena Das, Narender Kumar

{"title":"Overcoming the PROSP pseudogene challenge: accurate diagnosis of a novel PROS1 variant in a patient with dural venous sinus thrombosis.","authors":"Vasant Kumar, Debadrita Ray, Manu Jamwal, Chander Hans, Arihant Jain, Jasmina Ahluwalia, Reena Das, Narender Kumar","doi":"10.1097/MBC.0000000000001420","DOIUrl":"https://doi.org/10.1097/MBC.0000000000001420","url":null,"abstract":"Hereditary protein S deficiency, a risk factor for venous thromboembolism, presents diagnostic challenges due to the PROS1 gene's homologous pseudogene, PROSP. The pseudogene's homology risks co-amplification and misinterpretation of sequencing data, leading to false results and compromising clinical management. We report a case of a 28-year-old male who presented dural venous sinus thrombosis and low free protein S. After a novel PROS1 variant was identified via next-generation sequencing, a \"pseudogene-aware\" Sanger sequencing assay was developed to validate the finding. This assay utilized primers designed in silico method and high-temperature PCR to exploit nucleotide mismatches between PROS1 and PROSP, ensuring targeted amplification. The assay successfully validated a novel heterozygous missense variant, PROS1:c.1484T>C. This variant co-segregated with low protein S levels in the family and was classified as likely pathogenic. This pseudogene-aware strategy enabled the accurate identification of a novel variant causing severe thrombophilia, highlighting the importance of such assays for reliable molecular diagnosis and patient management.","PeriodicalId":520571,"journal":{"name":"Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis","volume":" ","pages":""},"PeriodicalIF":1.1,"publicationDate":"2026-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147501648","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Coexistence of two X-linked disorders: hemophilia A and G6PD deficiency. 两种x连锁疾病的共存：血友病A和G6PD缺乏症。

IF 1.1

Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis Pub Date : 2026-03-01 Epub Date: 2026-01-30 DOI: 10.1097/MBC.0000000000001404

Mustafa Ozay, Ugur Gumus, Ekrem Ünal

引用次数: 0

Effect of concurrent use of rivaroxaban or apixaban with amiodarone on international normalised ratio: a retrospective observational study. 利伐沙班或阿哌沙班与胺碘酮同时使用对国际标准化比率的影响：一项回顾性观察研究。

IF 1.1

Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis Pub Date : 2026-03-01 Epub Date: 2025-12-23 DOI: 10.1097/MBC.0000000000001405

Clarissa Kho, Karl Winckel, Kate Ziser, Vicky Lee, Sarah Mathers, Jennifer Bensley, Nina Raju

{"title":"Effect of concurrent use of rivaroxaban or apixaban with amiodarone on international normalised ratio: a retrospective observational study.","authors":"Clarissa Kho, Karl Winckel, Kate Ziser, Vicky Lee, Sarah Mathers, Jennifer Bensley, Nina Raju","doi":"10.1097/MBC.0000000000001405","DOIUrl":"10.1097/MBC.0000000000001405","url":null,"abstract":"The clearance of rivaroxaban and apixaban is mediated via cytochrome P450 3A4 (CYP3A4) and Permeability-glycoprotein (P-gp) at varying extents. Amiodarone, a weak CYP3A4 and moderate P-gp inhibitor, has the potential to reduce the clearance of these factor Xa (FXa) inhibitors. The real-world impact of this drug-drug interaction is unclear. Although international normalised ratio (INR) is not an accurate measure of FXa inhibitor effect, changes in INR may indicate changes in the impact of FXa inhibitors. To determine what effect the addition of amiodarone has on INR in patients concurrently prescribed rivaroxaban or apixaban in clinical practice. This retrospective observational study identified patients with atrial fibrillation prescribed rivaroxaban or apixaban from April 2017 to December 2022. INRs were analysed in patients prescribed rivaroxaban or apixaban with or without concomitant amiodarone. One hundred and forty-seven patients were included in the study and were separated into the following cohorts: patients prescribed apixaban alone, rivaroxaban alone, apixaban with amiodarone, or rivaroxaban with amiodarone. Mean INRs were greater for patients prescribed apixaban with amiodarone compared to those prescribed apixaban only (1.56 vs. 1.29, respectively) but not for patients prescribed rivaroxaban with amiodarone compared to patients prescribed rivaroxaban only (1.57 vs. 1.61, respectively). Four patients prescribed apixaban with amiodarone had INRs greater than or equal to 3. Our real-world data support literature suggesting that the amiodarone apixaban interaction is real and that there is a large inter-individual variability in the magnitude of this interaction. Further research analysing other coagulation markers (i.e. anti-Xa activity) is warranted to identify at-risk cohorts.","PeriodicalId":520571,"journal":{"name":"Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis","volume":" ","pages":"49-54"},"PeriodicalIF":1.1,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145822597","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Effects of cyclooxygenase and P2Y12 ADP receptor inhibitors on platelet phosphatidylserine exposure in vitro and in vivo. 环加氧酶和P2Y12 ADP受体抑制剂对血小板磷脂酰丝氨酸暴露的影响。

IF 1.1

Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis Pub Date : 2026-03-01 Epub Date: 2026-01-30 DOI: 10.1097/MBC.0000000000001406

Ivan A Muravlev, Olga A Antonova, Alexey V Mazurov

引用次数: 0

The effect of acetylsalicylic acid on thrombin generation in healthy volunteers. 乙酰水杨酸对健康志愿者凝血酶生成的影响。

IF 1.1

Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis Pub Date : 2026-01-01 Epub Date: 2025-12-01 DOI: 10.1097/MBC.0000000000001401

Alexa H Christophides, Samuel L Stanley, W Leif Ericksen, Lisa Senzel, Elliott Bennett-Guerrero

{"title":"The effect of acetylsalicylic acid on thrombin generation in healthy volunteers.","authors":"Alexa H Christophides, Samuel L Stanley, W Leif Ericksen, Lisa Senzel, Elliott Bennett-Guerrero","doi":"10.1097/MBC.0000000000001401","DOIUrl":"https://doi.org/10.1097/MBC.0000000000001401","url":null,"abstract":"This study assessed the effect of low-dose aspirin (81 mg) on thrombin generation in healthy volunteers using the calibrated automated thrombogram (CAT). This single-center prospective crossover study involved healthy volunteers, each serving as their own control. After Institutional Review Board approval and informed consent, healthy participants were administered aspirin (81 mg daily) for 7 days. Blood samples were collected at baseline, after the 7-day aspirin regimen, and 2 weeks postaspirin discontinuation. Platelet-poor plasma (PPP) samples were analyzed using CAT to measure endogenous thrombin potential (ETP) and other CAT parameters. The primary endpoint was change in ETP from baseline to after 7 days of aspirin. Data were analyzed with paired t tests. Data from 18 participants (ages 27-54) showed no significant change in ETP after aspirin administration (primary endpoint). Specifically, mean (standard deviation) ETP at baseline and on-aspirin were 1750 (237) vs. 1832 (301) nmol/l min, respectively. Secondary CAT parameters (lag time, peak thrombin generation, time to peak, and velocity index) also showed no significant differences. We did not observe a significant effect of low-dose aspirin (81 mg) for 7 days on any measure of thrombin generation in healthy volunteers. This study's controlled design in healthy subjects contrasts with previous studies that focused on patients where confounding effects of comorbidities and concomitant medications may have influenced the results.","PeriodicalId":520571,"journal":{"name":"Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis","volume":"37 1","pages":"38-40"},"PeriodicalIF":1.1,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145879842","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A comprehensive verification approach of coagulation analyser, analytical performance of the sysmex CS-2500. 综合验证混凝分析仪的方法，分析sysmex CS-2500的性能。

IF 1.1

Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis Pub Date : 2026-01-01 Epub Date: 2025-11-05 DOI: 10.1097/MBC.0000000000001395

Merve Sena Odabasi, Zeynep Mine Yalcinkaya Kara

引用次数: 0

Trends and demographic patterns of portal vein thrombosis mortality in the United States, 2018-2024. 2018-2024年美国门静脉血栓死亡率趋势和人口统计学模式

IF 1.1

Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis Pub Date : 2026-01-01 Epub Date: 2026-01-02 DOI: 10.1097/MBC.0000000000001398

Camilla Mattiuzzi, Giuseppe Lippi

引用次数: 0

Timeliness of hemostatic therapy administration for patients with bleeding disorders in the emergency department. 急诊科出血障碍患者止血治疗的时效性。

IF 1.1

Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis Pub Date : 2026-01-01 Epub Date: 2025-11-27 DOI: 10.1097/MBC.0000000000001399

Emily Kraft, Vanessa Bourck, Lisa Duffett, Alan Tinmouth, Tzu-Fei Wang, Roy Khalife

{"title":"Timeliness of hemostatic therapy administration for patients with bleeding disorders in the emergency department.","authors":"Emily Kraft, Vanessa Bourck, Lisa Duffett, Alan Tinmouth, Tzu-Fei Wang, Roy Khalife","doi":"10.1097/MBC.0000000000001399","DOIUrl":"10.1097/MBC.0000000000001399","url":null,"abstract":"Persons with bleeding disorders (PwBD) often face delays in receiving hemostatic therapies within the recommended 60-min window upon presenting to the emergency department, potentially exacerbating their conditions. We aimed to investigate the emergency department workflow for managing PwBD to identify inefficiencies and barriers to timely treatment. We conducted a retrospective cohort study of patients with hemophilia and von Willebrand disease (VWD) presenting to the emergency department from 2019 to 2022. Data were collected on patient demographics, disease type, severity, treatment type, and prescriber specialty. Time from triage to medication administration was the primary outcome. Statistical comparisons and Firth's penalized logistic regression were performed. Among 241 emergency department visits in 122 PwBD, 50% of the 86 bleeding events were treated with hemostatic therapies. Only 11% received them within 60 min. The median time from emergency department triage to administration of hemostatic therapies was 175 min [interquartile range (IQR) 93-364] for clotting factor concentrates (CFCs) and 206 min (IQR 152-269) for desmopressin. Important delays were observed in patient rooming, physician initial assessment, ordering and administration of hemostatic therapies. Patients triaged more urgently may have experienced higher odds of receiving hemostatic therapies in 60 min or less, though regression analysis did not identify statistically significant predictors of treatment beyond 60 min. This study highlights the urgent need for targeted interventions to address systemic challenges and mitigate treatment delays for PwBD in Canadian emergency department settings. Future research should focus on prospective evaluations of intervention effectiveness and the role of patient self-management in reducing emergency department dependency.","PeriodicalId":520571,"journal":{"name":"Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis","volume":" ","pages":"20-27"},"PeriodicalIF":1.1,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145644420","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Platelet secretion defects and increased CD63 expression in Hermansky-Pudlak syndrome: a case report - Erratum. Hermansky-Pudlak综合征中血小板分泌缺陷和CD63表达增高1例报告-勘误

IF 1.1

Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis Pub Date : 2026-01-01 Epub Date: 2026-01-02 DOI: 10.1097/MBC.0000000000001403

Massoumeh Shahbazi, Minoo Ahmadinejad

引用次数: 0